Atea Pharma (AVIR): Earnings per share for the last twelve months

Atea Pharmaceuticals (AVIR) relies on a proprietary ecosystem of oral antivirals, as confirmed by the trailing 12-month net profit per share chart on GURU.Markets, where -1.97 represents the current metric level. Primary risks are tied to the outcome of final-stage clinical trials against COVID-19, despite a substantial cash reserve. The non-cyclical demand for therapy provides the company with stability regardless of macroeconomic fluctuations.

Atea Pharmaceuticals (AVIR) - Net earnings per share (EPS TTM) from 07/04/2022 to 11/14/2026

Summary analytical data breakdowns for Atea Pharmaceuticals (AVIR)

- stock price and consensus target price:

Stock Price Atea Pharma|AVIR - Analyst Median Target

- stock exchange capitalization data:

Market Value Atea Corp|AVIR - Value Adjusted for Debt and Cash

- shareholders' equity book value data:

Accounting Value per Share Atea Pharmaceuticals|AVIR - Book Capitalization|Market Value to Book Value Ratio ateapharma.com|AVIR - Company Total Asset Base

- debt obligations and liquidity statistics:

Total Debt to Capital Atea Pharmaceuticals|AVIR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Atea Pharmaceuticals Inc|AVIR - Company Cumulative Indebtedness|Debts to Book Capitalization Atea Pharmaceuticals, Inc.|AVIR - Long-Term Debt|Company Short-Term Debts Atea Pharmaceuticals|Quick Liquidity Indicator ateapharma.com

- earnings and valuation multiples indicators:

AVIR - Final Profit|Expected Profit Atea Pharmaceuticals|AVIR - Market Cap to Net Income|Forward P/E Multiple Atea Pharmaceuticals Inc|AVIR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Atea Pharma|AVIR - Operating profit EBITDA|Earnings per share for the last twelve months Atea Pharmaceuticals|AVIR - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ateapharma.com|AVIR - Net earnings per share growth this year|Earnings growth forecast for next year Atea Pharmaceuticals

- sales and revenue data:

AVIR - Revenue and Sales Volume|Projected Sales Volume Atea Pharma|AVIR - Market Cap to Revenue|Forward P/S Multiple Atea Pharmaceuticals, Inc.

Summary company analytics:Atea Corp (AVIR)

This chart reflects the rolling trailing twelve-month earnings per share, allowing for an assessment of actual return on equity without distortions caused by the number of outstanding shares. For Atea Pharmaceuticals (AVIR), the rolling 12-month per-share income metric highlights pre-commercial stage risks, where a narrow specialization in antiviral drugs makes financial stability dependent on clinical trial outcomes.

Main competitors